ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.2706del (p.Glu902fs)

dbSNP: rs1597868211
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000826189 SCV000967735 pathogenic Hereditary breast ovarian cancer syndrome 2018-09-13 criteria provided, single submitter clinical testing The p.Glu902AspfsX98 variant in BRCA1 has not been previously reported in indivi duals with BRCA1-associated cancer or in large population studies. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequen ce beginning at position 902 and leads to a premature termination codon 98 amino acids downstream. This alteration is then predicted to lead to a truncated or a bsent protein. Heterozygous loss of function of the BRCA1 gene is an established disease mechanism in autosomal dominant hereditary breast and ovarian cancer (H BOC). Additionally, other loss of function variants located in the same exon as the p.Glu902AspfsX98 variant have been reported in individuals with HBOC (HGMD; Stenson 2017). In summary, this variant meets criteria to be classified as patho genic for HBOC in an autosomal dominant manner based on absence from controls an d its predicted impact on the protein. ACMG/AMP criteria applied: PM2, PVS1.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.